The PERT Consortium invites you to listen to a series of podcasts moderated by past immediate president of PERT Consortium Victor Tapson, MD, and joined by Alex Spyropoulos, MD, as they discuss dedicated DOAC trials that evaluated the treatment of pulmonary embolism including initial treatment, early discharge of low-risk PE patients, and extension of treatment to reduce the risk of recurrence.

 

Victor Tapson, MD

Victor Tapson, MD
Immediate Past PERT President
Cedar Sinai Medical Center
Pulmonary & Critical Care
Alex Spyropoulos, srcset=

Alex Spyropoulos, MD
Internist and Hospitalist
Professor, Donald and Barbara Zucker
School of Medicine at Hofstra/Northwell

 


 

Content co-developed by the featured PERT Consortium speakers and Janssen Pharmaceuticals, Inc. (“Janssen”). Speakers are paid by PERT Consortium through sponsorship funds provided by Janssen.

 


 

Dedicated DOAC Trials for the Treatment of Pulmonary Embolism: Part 1 – A Dedicated PE Trial

The PERT Consortium invites you to listen to a podcast moderated by past immediate president of PERT Consortium Victor Tapson, MD, and joined by Alex Spyropoulos, MD, as they discuss dedicated DOAC trials that evaluated the treatment of pulmonary embolism.

 

Dedicated DOAC Trials for the Treatment of Pulmonary Embolism: Part 2 – Low-Risk PE Discharged Early

The PERT Consortium invites you to listen to a podcast moderated by past immediate president of PERT Consortium Victor Tapson, MD, and joined by Alex Spyropoulos, MD, as they discuss clinical trial data on early hospital discharge of patients with a low-risk PE, risk stratification tools, as well as recent guideline recommendations.

 

Dedicated DOAC Trials for the Treatment of Pulmonary Embolism: Part 3 – Extended VTE Treatment and the 2019 ESC Guidelines

The PERT Consortium invites you to listen to a podcast moderated by past immediate president of PERT Consortium Victor Tapson, MD, and joined by Alex Spyropoulos, MD, as they discuss extension of VTE treatment with a DOAC to reduce the risk of recurrence and the 2019 ESC Guidelines on extension of treatment.

 


 

[safetyinfo]